TACO

Business Context and Reporting Period

Company: Berto Acquisition Corp. (TACO/TACOU/TACOW)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Model: Cayman Islands exempted company (SPAC) formed to effect a merger, share exchange, or asset acquisition with one or more target businesses. The Company has no operating history and generates no operating revenue.
Key Milestone: Consummated Initial Public Offering (IPO) on May 1, 2025, raising $300.15 million in gross proceeds. A non-binding Letter of Intent (LOI) with OnMed LLC entered in October 2025 expired in March 2026 without a definitive agreement.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Generation: The Company transitioned from a pre-IPO entity with no assets to a public company with $308.7 million in the Trust Account. Net income of $7.9 million in 2025 contrasts with a net loss of $738,290 in the period from inception (July 2024) through December 31, 2024. The 2025 income is primarily driven by $8.51 million in investment income from the Trust Account.
• Liquidity Position: Cash outside the Trust Account increased from $34,044 in 2024 to $578,683 in 2025, funded by IPO proceeds held outside the Trust and related party advances.
• Capital Structure: Following the May 2025 IPO, the Company issued 30,015,000 Public Shares and 7,503,750 Founder Shares. The underwriters fully exercised their over-allotment option, removing forfeiture conditions on Founder Shares.

Guidance, Outlook, Risks, and Contingencies

Outlook & Strategy: The Company has 24 months from the IPO closing (until May 1, 2027) to consummate an initial business combination. Management focuses on targets in AI, wellness, longevity, and aesthetics with enterprise values between $200 million and $1.5 billion. No definitive agreement is currently in place following the expiration of the OnMed LOI.

Management Commentary: Management believes current liquidity (cash outside Trust plus access to Sponsor advances) is sufficient to fund operations for at least one year. The Sponsor has agreed to provide working capital loans if necessary, up to $1.5 million, which may be convertible to warrants.

Risks & Contingencies:

• Liquidation Risk: If no business combination is completed by May 1, 2027, the Company will liquidate and redeem Public Shares at a pro-rata share of the Trust Account (approx. $10.28 per share as of Dec 31, 2025, subject to change).
• Redemption Risk: Significant shareholder redemptions could reduce cash available for a transaction, potentially forcing the Company to seek additional financing or abandon a deal.
• Geopolitical & Market Risks: Global conflicts (Russia-Ukraine, Middle East) and market volatility may impact the ability to find or finance a target.
• Related Party Conflicts: Sponsor and management hold Founder Shares at a nominal price (~$0.003/share), creating potential conflicts of interest regarding the selection of a target.

Investor Verification Checklist

• Trust Account Yield: Verify the current interest rate earned on the Trust Account to assess the redemption value per share if liquidation occurs.
• Related Party Debt: Confirm the status of the $322,000 "Due to related party" balance and any subsequent repayments (Note: $250,000 was repaid subsequent to Dec 31, 2025).
• Extension Provisions: Review the Articles of Association for specific terms regarding shareholder approval required to extend the 24-month completion window.
• Deferred Fees: Note that $11.7 million in underwriting fees are contingent on the successful completion of a business combination.
• Target Pipeline: Monitor for new LOIs or definitive agreements, as the previous target (OnMed) was not pursued.